Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M Kuderer,Toni K Choueiri,Dimpy P Shah,Yu Shyr,Samuel M Rubinstein,Donna R Rivera,Sanjay Shete,Chih-Yuan Hsu,Aakash Desai,Gilberto de Lima Lopes Jr,Petros Grivas,Corrie A Painter,Solange Peters,Michael A Thompson,Ziad Bakouny,Gerald Batist,Tanios Bekaii-Saab,Mehmet A Bilen,Nathaniel Bouganim,Mateo Bover Larroya,Daniel Castellano,Salvatore A Del Prete,Deborah B Doroshow,Pamela C Egan,Arielle Elkrief,Dimitrios Farmakiotis,Daniel Flora,Matthew D Galsky,Michael J Glover,Elizabeth A Griffiths,Anthony P Gulati,Shilpa Gupta,Navid Hafez,Thorvardur R Halfdanarson,Jessica E Hawley,Emily Hsu,Anup Kasi,Ali R Khaki,Christopher A Lemmon,Colleen Lewis,Barbara Logan,Tyler Masters,Rana R McKay,Ruben A Mesa,Alicia K Morgans,Mary F Mulcahy,Orestis A Panagiotou,Prakash Peddi,Nathan A Pennell,Kerry Reynolds,Lane R Rosen,Rachel Rosovsky,Mary Salazar,Andrew Schmidt,Sumit A Shah,Justin A Shaya,John Steinharter,Keith E Stockerl-Goldstein,Suki Subbiah,Donald C Vinh,Firas H Wehbe,Lisa B Weissmann,Julie Tsu-Yu Wu,Elizabeth Wulff-Burchfield,Zhuoer Xie,Albert Yeh,Peter P Yu,Alice Y Zhou,Leyre Zubiri,Sanjay Mishra,Gary H Lyman,Brian I Rini,Jeremy L Warner,COVID-19 and Cancer Consortium,Maheen Abidi,Jared D Acoba,Neeraj Agarwal,Syed Ahmad,Archana Ajmera,Jessica Altman,Anne H Angevine,Nilo Azad,Michael H Bar,Aditya Bardia,Jill Barnholtz-Sloan,Briana Barrow,Babar Bashir,Rimma Belenkaya,Stephanie Berg,Eric H Bernicker,Christine Bestvina,Rohit Bishnoi,Genevieve Boland,Mark Bonnen,Gabrielle Bouchard,Daniel W Bowles,Fiona Busser,Angelo Cabal,Paolo Caimi,Theresa Carducci,Carla Casulo,James L Chen,Jessica M Clement,David Chism,Erin Cook,Catherine Curran,Ahmad Daher,Mark Dailey,Saurabh Dahiya,John Deeken,George D Demetri,Sandy DiLullo,Narjust Duma,Rawad Elias,Bryan Faller,Leslie A Fecher,Lawrence E Feldman,Christopher R Friese,Paul Fu,Julie Fu,Andy Futreal,Justin Gainor,Jorge Garcia,David M Gill,Erin A Gillaspie,Antonio Giordano,Mary Grace Glace,Axel Grothey,Shuchi Gulati,Michael Gurley,Balazs Halmos,Roy Herbst,Dawn Hershman,Kent Hoskins,Rohit K Jain,Salma Jabbour,Alokkumar Jha,Douglas B Johnson,Monika Joshi,Kaitlin Kelleher,Jordan Kharofa,Hina Khan,Jeanna Knoble,Vadim S Koshkin,Amit A Kulkarni,Philip E Lammers,John C Leighton Jr,Mark A Lewis,Xuanyi Li,Ang Li,K M Steve Lo,Arturo Loaiza-Bonilla,Patricia LoRusso,Clarke A Low,Maryam B Lustberg,Daruka Mahadevan,Abdul-Hai Mansoor,Michelle Marcum,Merry Jennifer Markham,Catherine Handy Marshall,Sandeep H Mashru,Sara Matar,Christopher McNair,Shannon McWeeney,Janice M Mehnert,Alvaro Menendez,Harry Menon,Marcus Messmer,Ryan Monahan,Sarah Mushtaq,Gayathri Nagaraj,Sarah Nagle,Jarushka Naidoo,John M Nakayama,Vikram Narayan,Heather H Nelson,Eneida R Nemecek,Ryan Nguyen,Pier Vitale Nuzzo,Paul E Oberstein,Adam J Olszewski,Susie Owenby,Mary M Pasquinelli,John Philip,Sabitha Prabhakaran,Matthew Puc,Amelie Ramirez,Joerg Rathmann,Sanjay G Revankar,Young Soo Rho,Terence D Rhodes,Robert L Rice,Gregory J Riely,Jonathan Riess,Cameron Rink,Elizabeth V Robilotti,Lori Rosenstein,Bertrand Routy,Marc A Rovito,M Wasif Saif,Amit Sanyal,Lidia Schapira,Candice Schwartz,Oscar Serrano,Mansi Shah,Chintan Shah,Grace Shaw,Ardaman Shergill,Geoffrey Shouse,Heloisa P Soares,Carmen C Solorzano,Pramod K Srivastava,Karen Stauffer,Daniel G Stover,Jamie Stratton,Catherine Stratton,Vivek Subbiah,Rulla Tamimi,Nizar M Tannir,Umit Topaloglu,Eli Van Allen,Susan Van Loon,Karen Vega-Luna,Neeta Venepalli,Amit K Verma,Praveen Vikas,Sarah Wall,Paul L Weinstein,Matthias Weiss,Trisha Wise-Draper,William A Wood,Wenxin Vincent Xu,Susan Yackzan,Rosemary Zacks,Tian Zhang,Andrea J Zimmer,Jack West
DOI: https://doi.org/10.1016/S0140-6736(20)31187-9
2020-06-20
Abstract:Background: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods: In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing. Findings: Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Interpretation: Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. Funding: American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.